Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?

Core Viewpoint - Gilead Sciences experienced a significant stock increase of nearly 6% following favorable Q4 results, with a notable 100% gain over the past two years, reaching an all-time high of $157 per share [1]. Q4 Results - Gilead reported Q4 sales of $7.92 billion, a 5% increase from $7.56 billion in the same quarter last year, exceeding estimates of $7.57 billion [2]. - The HIV franchise sales grew by 6%, driven by strong demand for products like Biktarvy and Descovy, while liver disease revenue rose by 17%, led by Livdelzi [2]. - Net income for the quarter was $2.2 billion, translating to an adjusted EPS of $1.86, which surpassed expectations of $1.83 despite a decline from $1.90 per share a year ago [2]. Full Year Results & Guidance - For FY25, Gilead's EPS is projected to spike by 76% to $8.15 compared to $4.62 per share in 2024, with annual sales increasing over 2% to $29.44 billion [4]. - Gilead's guidance for FY26 anticipates annual sales between $29.6 billion and $30 billion, slightly below Wall Street's estimate of $30.04 billion, but the top end of EPS guidance ($8.45-$8.85) exceeds expectations of $8.61 [5]. Valuation and Dividend - Gilead's valuation remains attractive at 17X forward earnings, which is below the S&P 500 average and the industry average of 19X [6]. - The company offers a 2.15% annual dividend yield, higher than the S&P 500's average of 1.07%, with a payout ratio of 39% [8][9]. Return on Invested Capital (ROIC) - Gilead has a return on invested capital (ROIC) of 24%, significantly higher than many biopharmaceutical companies, which typically have ROIC in the mid-teens or single digits due to high R&D investments [10]. Investment Outlook - Following the favorable Q4 results, Gilead Sciences holds a Zacks Rank 3 (Hold), presenting an intriguing option for long-term investors seeking value and income [11].